Drug-Eluting Stents Market

The global drug-eluting stents market was valued at $6,382 million in 2019, and is projected to reach $8,777 million by 2027, registering a CAGR of 8.7% from 2020 to 2027.

Drug-eluting stent (DES) is a peripheral or coronary stent placed into narrowed, diseased peripheral, or coronary arteries that slowly release a drug to block cell proliferation. Drug-eluting stents are coated with medication, which is released (eluted) to prevent growth of scar tissues in arterial walls. Eluted drug helps arteries to remain smooth and exposed, which ensures adequate blood flow and decrease in chances of restenosis. DES is regarded as the gold standard for treatment of coronary heart disease, as it offers various benefits such as enhanced vessel healing, minimally invasive nature, and reduced need for prolonged dual antiplatelet therapy. Patients implanted with DES are recommended to use certain medications or drug therapy. This therapy helps to decrease the risk of in-stent thrombosis, owing to a comparatively slower healing process.

Constant rise in geriatric population primarily drives growth of the drug-eluting stents market as geriatric population is at high risk of developing arterial disorders. In addition, unhealthy food habits, sedentary lifestyles, and lack of exercise increase the prevalence of atherosclerosis worldwide, which propels growth of the market. Moreover, rise in drug eluting stents product approvals and minimally-invasive techniques for DES placing augments growth of the drug eluting stent market. Furthermore, rise in prevalence of several cardiovascular diseases such as abnormal heart rhythms, heart attack, heart valve disease, congenital heart diseases, and heart failure function is expected to boost the growth of the market. However, stringent government regulations for product approval restricts growth of the market. Conversely, rise in potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period.

COVID-19 pandemic has affected every industry worldwide. For instance, after COVID-19 was declared as a pandemic by the WHO, countries worldwide adopted nationwide lockdowns to observe social distancing as a measure to contain the spread. This led to disruption, limitation, challenges, and changes in each sector of every industry. Similarly, manufacturing and distributing companies drug-eluting stents have been affected by COVID-19 to a limited extent, owing to shutdowns in various COVID-19 affected countries and rise in number of healthcare workers falling ill in the wake of the COVID-19 pandemic, leading to short supply. 

Drug-eluting Stents Market Segmentation  

The global drug-eluting stents market is segmented on the basis of coating, application, end user, and region. On the basis of coating, the market is divided into polymer-based coating and polymer free coating. The polymer-based coating segment is further bifurcated into biodegradable and non-biodegradable. The polymer free coating segment is further divided into microporous surface, microstructured surface, slotted tubular surface, and nanoporous surface. By application, the market is categorized into coronary artery disease and peripheral artery disease. By end user, the market is bifurcated into hospitals, ambulatory surgical centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

Segment review 

Presently, on the basis of coating, the polymer free coating segment is the major revenue contributor, and is projected to grow significantly during the forecast period. High adoption of DES is attributed to lower in-stent restenosis rates, quicker drug eluting rate, and higher drug loading capacity of nanoporous surfaces. Moreover, polymer free coating offers advantages such as inflammatory issues produced by polymers used in stents can be avoided by excluding polymer coating completely and releasing anti-proliferative drug directly from the stent surface.

By application, the coronary artery disease segment is the major shareholder in the global drug-eluting stents market, owing to rise in prevalence of coronary artery disease, surge in adoption of drug-eluting stents, and increase in product approvals of drug-eluting stents in coronary artery disease treatment.  

Snapshot of Asia-Pacific drug-eluting stents market  

Asia-Pacific presents lucrative opportunities for key players operating in the drug-eluting stents market, owing to increase in prevalence of coronary artery disease and peripheral artery disease, growth in patient awareness toward commercial availability of products, increase in geriatric population in emerging economies, development of the R&D sector, rise in healthcare reforms, and technological advancements in drug-eluting stents products. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive growth of the drug-eluting stents market in the region.

The key players profiled in this report include Abbott Laboratories, Alvimedica, B. Braun Holding GmbH & Co. KG, Biosensors International Group, Biotronik Inc., Boston Scientific Corporation, Cook Group (Cook Medical), Medtronic Plc, Stentys SA, and Terumo Corporation.

Key Benefits For Stakeholders

• The study provides an in-depth analysis of the drug-eluting stents market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers drug-eluting stents market analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on prevailing opportunities in the market.
• A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global drug-eluting stents market growth.

 Drug-Eluting Stents Market Report Highlights